Experience in administration of cholinolytics in the treatment of patients with prostatic adenoma and symptoms of the lower urinary tract


Cite item

Full Text

Abstract

References

  1. Speakman M. J., Kirby R. S., Joyce A. et al. Guideline for the primary care management of male lower urinary tract symptoms. Br. J. Urol. Int. 2004; 93: 985-990.
  2. Jacobsen S. J., Girman C. J., Jacobson D. J. et al. Long-term (92-month) natural history of changes in lower urinary tract symptom severity. J. Urol. (Baltimore) 2000; 163 (Suppl. 4): 248-249.
  3. Emberton M., Cornel E. B., Bassi P. F. et al. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int. J. Clin. Pract. 2008; 62 (7): 1076-1086.
  4. Parsons J. K., Wilt T. J., Wang P. Y. et al. Progression of lower urinary tract symptoms in older men: a community based study. J. Urol. (Baltimore) 2010; 183: 1915-1920.
  5. Roehrborn C. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. Br. J. Urol. Int. 2008; 101 (Suppl.) 3): 17-21.
  6. Marberger M., Harkaway R., de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. Eur. Urol. 2004; 45: 411-419.
  7. Sarma A. V., Jacobson D. J., McGree M. E. et al. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J. Urol. (Baltimore) 2005; 173: 2048-2053.
  8. Hutchison A., Farmer R., Verhamme et al. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur. Urol. 2007; 51: 207-216.
  9. Boyle P., Could A. I., Roehrborn C. G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia. Urology 1996; 48: 398-405.
  10. Abrams P., Wein A. J. The overactive bladder: from basic science to clinical management. Urology 1997; 50 (Suppl. 6A): 1-144.
  11. Irwin D. E., Milsom I., Hunskaar S. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 2006; 50: 1306-1315.
  12. Milsom I., Abrams P., Cardozo L. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br. J. Urol. Int. 2001; 87: 760-766.
  13. Wein A. J., Rackley R. R. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J. Urol. (Baltimore) 2006; 175: 5-10.
  14. Peters T. J., Donovan J. L., Kay H. E. et al. The ICS-"BPH" Study: the bothersomeness of urinary symptoms. J. Urol. (Baltimore) 1997; 157 (3): 885-889.
  15. Hyman M. J., Groutz A., Blaivas J. G. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J. Urol. (Baltimore) 2001; 166 (2): 550-553.
  16. Oelke M., Baard J., Wijkstra H. et al. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur. Urol. 2008; 54: 419-426.
  17. Abdel-Aziz K. F., Lemack G. E. Overactive bladder in the male patient: bladder, outlet, or both? Curr. Urol. Rep. 2002; 3: 445- 451.
  18. de Nunzio C., Franco G., Rocchegiani A. et al. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J. Urol. (Baltimore) 2003; 169: 535-539.
  19. Thomas A. W., Cannon A., Bartlett E. et al. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. Br. J. Urol. Int. 2004; 93: 745-750.
  20. Kaplan S. A., Walmsley K., Te A. E. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplalsia. J. Urol. (Baltimore) 2005; 174: 2273-2276.
  21. Lee J. Y., Kim H. W., Lee S. J. et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. Br. J. Urol. Int. 2004; 94: 817-820.
  22. Okada H., Shirakawa T., Muto S. et al. Propiverine hydrochloride relieves irritative symptoms of benign prostatic hyperplasia. J. Urol. (Baltimore) 2004; 171 (4, Suppl.): 357-358.
  23. Lim E., Chia S. J. Combination therapy using alpha-blocker and antimuscarinic drugs in men with lower urinary tract symptoms suggestive of bladder outlet obstruction and an overactive bladder: is it safe and efficacious? In: Proceedings of the ICS 35-th Annual Meeting. Montréal; 2005; Abstr. 205.
  24. Blake-James B. T., Rashidian A., Ikeda Y., Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Br. J. Urol. Int. 2006; 99: 85-96.
  25. McGuire E. J., Savastano J. A. Effect of alphaadrenergic blockade and anticholinergic agents on the decentralized primate bladder. Neurourol. and Urodyn. 1985; 4: 139.
  26. Athanasopoulos A., Gyftopoulos K., Giannitsas K. et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J. Urol. (Baltimore) 2003; 169: 2253-2256.
  27. Kyu-Sung Lee, Myung-Soo Choo, Duk-Yoon Kim et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J. Urol. 2005; 174: 1334-1338.
  28. Male lower urinary tract dysfunction: evaluation and management. In: McConnell J. et al., eds. 6-th International consultation on new developments in prostate cancer and prostate diseases. Paris: Health Publications; 2006.
  29. Kaplan S. A., Roehrborn C. G., Rovner E. S. et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. J. A. M. A. 2006; 296: 2319-2328.
  30. Reynard J. M. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr. Opin. Urol. 2004; 14Ж 13-16.
  31. Ruggieri M. R. Jr., Braverman A. S., Pontari M. A. Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J. Urol. (Baltimore) 2005; 174: 1743-1748.
  32. Athanasopoulos A., Perimenis P. Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Expert. Opin. Pharmacother. 2005; 6 (14): 2429- 2433.
  33. Greco K. A., McVary K. T. The role of combination medical therapy in benign prostatic hyperplasia. Int. J. Impot. Res. 2008; 20 (Suppl. 3): S33-S43.
  34. Kaplan S. A., Roehrborn C. G., Chancellor M. et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. Br. J. Urol. Int. 2008; 102 (9): 1133-1139.
  35. Rovner E. S., Kreder K., Sussman D. O. et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J. Urol. 2008; 180: 1034-1041.
  36. Chapple Ch., Herschorn S., Abrams P. et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with a-blockers. Eur. Urol. 2009; 56: 534- 543.
  37. Roehrborn C. G., Kaplan S. A., Jones S. et al. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur. Urol. 2009; 55: 472-481.
  38. Gravas S., Melekos M. D. Male lower urinary tract symptoms: How do symptoms guide our choice of treatment? Curr. Opin. Urol. 2009; 19 (1): 49-54.
  39. Chapple Ch. Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. Curr. Opin. Urol. 2010; 20: 43-48.
  40. Kaplan S. A., McCammon K., Fincher R. et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J. Urol. (Baltimore) 2009; 182: 2825-2830.
  41. Guidelines on conservative treatment of non-neurogenic male LUTS / Oelke M., Bachmann A., Descazeaud A. et al. 2010.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies